Clinical trials
Pheochromocytoma/Paraganglioma (PPGL) clinical trials
Below are recruiting pheochromocytoma/paraganglioma (ppgl) clinical trials, each written for real people, not researchers. We’re tracking 5 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT04924075RecruitingPhase 2
Belzutifan for cancers linked to VHL or HIF-2α changes
This Phase 2 study tests belzutifan (MK-6482) to treat certain advanced cancers caused by specific gene or disease changes, including VHL-related tumors and HIF-2α related tumors. It may help shrink tumors or slow their growth in people whose cancer matches these genetic or disease patterns.
Los Angeles, CaliforniaAges 12 years+ - NCT06503146RecruitingPhase 2
New imaging tracer for detecting various cancers
This trial tests a new imaging agent, [18F]FAPI-74, which might help detect certain cancers more clearly. The scan looks for a protein called fibroblast activation protein (FAP) that is often found in tumors. If you have one of the listed cancers and are about to start treatment, this study could help doctors see where the cancer is and how it responds to therapy.
Bethesda, MarylandAges 18–120 - NCT07288931Recruiting
PET/CT Scan for Pheochromocytoma and Paraganglioma
This trial uses a special PET/CT scan called Al18F-NOTA-LM3 to help doctors see pheochromocytoma and paraganglioma tumors more clearly. It may help find out if you have these tumors and guide your treatment.
Beijing, Beijing MunicipalityAges 18–80 - NCT07182175Enrolling by invitation
Heart health during adrenal tumor surgery study
This study looks at how different types of adrenal tumors might affect the heart during and after surgery. It aims to help doctors understand and reduce the risk of heart injury in patients having these tumors removed.
BeijingAges 18 years+ - NCT07680205RecruitingPhase 2
Study of Belzutifan for Pheochromocytoma or Paraganglioma
This trial tests a drug called belzutifan to see how it affects hormone levels in people with rare adrenal tumors (pheochromocytoma or paraganglioma). It may help control symptoms caused by excess hormones.
Cambridge, CambridgeshireAges Any age
Hear when a new Pheochromocytoma/Paraganglioma (PPGL) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for pheochromocytoma/paraganglioma (ppgl)?
- Yes. Clin2 currently lists 5 recruiting pheochromocytoma/paraganglioma (ppgl) studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a pheochromocytoma/paraganglioma (ppgl) trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a pheochromocytoma/paraganglioma (ppgl) trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.